N@N

Ami Fadia Reiterated (BPMC) at Strong Buy and Held Target at $97 on, Feb 26th, 2024

Ami Fadia of Needham, Reiterated "Blueprint Medicines Corporation" (BPMC) at Strong Buy and Held Target at $97 on, Feb 26th, 2024.

Ami has made no other calls on BPMC in the last 4 months.

There are 9 other peers that have a rating on BPMC. Out of the 9 peers that are also analyzing BPMC, 2 agree with Ami's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Peter Lawson of "Barclays" Maintained at Hold with Increased Target to $70 on, Tuesday, February 13th, 2024
• Michael Ulz of "Morgan Stanley" Maintained at Hold with Increased Target to $63 on, Friday, October 27th, 2023

These are the ratings of the 7 analyists that currently disagree with Ami

---

• David Lebowitz of "Citigroup" Maintained at Strong Sell with Increased Target to $65 on, Friday, February 16th, 2024
• Reni Benjamin of "JMP Securities" Reiterated at Buy and Held Target at $114 on, Friday, February 16th, 2024
• Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $97 on, Tuesday, January 9th, 2024
• Dane Leone of "Raymond James" Maintained at Strong Buy with Increased Target to $100 on, Friday, December 22nd, 2023
• Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $115 on, Tuesday, December 19th, 2023
• Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $85 on, Monday, December 11th, 2023
• Matthew Biegler of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $85 on, Friday, October 27th, 2023

Contributing Sources

---